These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33861693)

  • 1. The Search for a Drug to End Alzheimer's.
    Campbell S
    IEEE Pulse; 2021; 12(2):2-7. PubMed ID: 33861693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Making the Case for Accelerated Withdrawal of Aducanumab.
    Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
    J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update: FDA approval of Biogen's aducanumab.
    Hollmann P
    Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638
    [No Abstract]   [Full Text] [Related]  

  • 4. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
    Lythgoe MP; Prasad V
    Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
    [No Abstract]   [Full Text] [Related]  

  • 6. Alzheimer's and Aducanumab: Unjust Profits and False Hopes.
    Fleck LM
    Hastings Cent Rep; 2021 Jul; 51(4):9-11. PubMed ID: 34156732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian perspective on Biogen's aducanumab trial.
    Temp AGM; Ly A; van Doorn J; Wagenmakers EJ; Tang Y; Lutz MW; Teipel S
    Alzheimers Dement; 2022 Nov; 18(11):2341-2351. PubMed ID: 35235700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we learn lessons from the FDA's approval of aducanumab?
    Liu KY; Howard R
    Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 10. Making the Case for the Accelerated Withdrawal of Aducanumab.
    Whitehouse PJ; Saini V
    J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
    Maulden A
    Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
    Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
    Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
    DiStefano MJ; Alexander GC; Polsky D; Anderson GF
    J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated Approval of Aducanumab: Where Do We Stand Now?
    Barenholtz Levy H
    Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.
    Herder M
    J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Alzheimer's drug clears FDA advisory vote despite unknowns.
    Couzin-Frankel J
    Science; 2024 Jun; 384(6701):1164-1165. PubMed ID: 38870282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The need to show minimum clinically important differences in Alzheimer's disease trials.
    Liu KY; Schneider LS; Howard R
    Lancet Psychiatry; 2021 Nov; 8(11):1013-1016. PubMed ID: 34087114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aducanumab (Aduhelm) for Alzheimer's disease.
    Med Lett Drugs Ther; 2021 Jul; 63(1628):105-106. PubMed ID: 34543258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.